Alyeska Investment Group, L.P. Larimar Therapeutics, Inc. Transaction History
Alyeska Investment Group, L.P.
- $23.4 Billion
- Q1 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,442,473 shares of LRMR stock, worth $2.86 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,442,473
Previous 984,077
46.58%
Holding current value
$2.86 Million
Previous $3.76 Million
17.5%
% of portfolio
0.01%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding LRMR
# of Institutions
108Shares Held
64.5MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$42 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$12 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$11 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$9.46 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$6.76 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $85.7M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...